Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2018 07:00 ET | Source: uniQure Inc.

uniQure Announces to Present at Multiple Conferences in May

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 27, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that it will be featured in multiple...
April 25, 2018 16:15 ET | Source: uniQure Inc.

uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington’s Disease at the 2018 American Academy of Neurology Annual Meeting

~ Mutant Huntingtin Protein Reduced by a Median of 68% in the Deep Structures of the Brain and a Median of 47% in the Frontal Cortex at 6 Months in a Large Diseased Animal Model ~ LEXINGTON, Mass....
March 14, 2018 07:00 ET | Source: uniQure Inc.

uniQure Announces 2017 Financial Results and Recent Company Progress

~ On Track to Begin Pivotal Study of AMT-061 in Hemophilia B in Q3 2018 ~ Submitted IND Amendment for AMT-061 Dose Confirmation Study, with Topline Data Expected by End of 2018 ~ Expects IND...
February 27, 2018 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Conferences in March

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 27, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that it will be featured in multiple...
February 01, 2018 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Conferences in February

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 01, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that members of company management or...
January 22, 2018 07:00 ET | Source: uniQure Inc.

uniQure Receives Orphan Medicinal Product Designation in Europe for AMT-130 in Huntington’s disease

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 22, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
January 08, 2018 07:00 ET | Source: uniQure Inc.

uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value

~ Pivotal Trial in Hemophilia B on Track to Begin in Q3 2018, with Initial AMT-061 Clinical Data by Year End ~ ~ AMT-130 Expected to be First AAV-Based Gene Therapy for Huntington’s Disease to Enter...
December 18, 2017 07:00 ET | Source: uniQure Inc.

uniQure Announces Publication in the Journal Blood of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 18, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
December 11, 2017 16:01 ET | Source: uniQure Inc.

uniQure Added to NASDAQ Biotechnology Index

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 11, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
December 11, 2017 07:00 ET | Source: uniQure Inc.

uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B

– Clinical Benefit Maintained in All Patients, with Durable Increases in FIX Clotting Activity at Up to Two Years of Follow-Up – – Second Dose Cohort Demonstrated 89% Reduction in Spontaneous Bleeds,...